The purpose of this study is to see if it is safe to give L-743,872 to men with candidal
esophagitis, an AIDS-related yeast infection in the esophagus.
In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of
three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the
final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
You may be eligible for this study if you:
- Are an 18- to 65-year-old man with candidal esophagitis.